FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203399391> ?p ?o ?g. }

• W3203399391 endingPage "103308" @default.
• W3203399391 startingPage "103308" @default.
• W3203399391 abstract "The use of disease-modifying agents (DMAs) to treat Multiple Sclerosis (MS) in older adults is debated as the disease activity decreases with aging. However, limited data exist regarding prescribing patterns of DMAs among older adults with MS.To examine prescribing patterns of DMAs and the factors associated with DMA prescribing practices among older adults with MS using electronic medical records (EMR) data.A retrospective longitudinal cohort study was conducted using the TriNetX, a federated EMR network from the US, data from 2016 to 2019. The study included older adults (≥60 years) with MS diagnosis and at least one prescription record during the study period. Patients with DMA prescriptions were identified and further classified into injectable, oral, or infusion users based on their last DMA prescription. A multivariable logistic regression model was used to evaluate the factors associated with prescribing of DMAs. A multinomial logistic regression model was also used to determine the factors associated with prescribing a particular dosage form of DMA.The study cohort consisted of 12,922 older adults with MS, with 2,455 (18.99%) receiving DMA prescriptions. The commonly prescribed DMAs were injectables (10.46%), followed by orals (6.06%) and infusions (2.40%). Multivariable logistic regression revealed that older adults between 60- to 64 years (Adjusted Odds Ratio [aOR]= 2.38) and 65-69 years (aOR=1.60) had higher odds of receiving DMA compared to older adults of 70 years and above. African Americans (aOR=1.71) had higher odds of receiving DMA prescriptions compared to Caucasians. The presence of symptoms (pain, fatigue, speech, walking difficulty) and use of symptomatic medication (anti-fatigue medication, bladder dysfunction medication, antispasmodics, antidepressants, and relapse medication) increased the odds of being prescribed DMAs. Multinomial logistic regression found that patients 60-64 years of age had higher odds of being prescribed infusion (aOR, 95% Confidence Interval [CI] =2.06, 1.35-3.15) and oral (65-69 years: aOR=1.60, 1.24-2.07) over injectable DMAs compared to the older adults aged 70 years and above.Older males (aOR=1.68, 95% CI: 1.23-2.30) were associated with increased odds of being prescribed infusion DMA over injectable DMA compared to females. The presence of comorbidities such as coagulopathy and peripheral vascular disorders decreased the odds of being prescribed oral DMA over injectable DMA. Patients with cerebellar symptoms had an increased likelihood of being prescribed with an infusion DMA over injectable DMA. Patients using drugs for treating relapses had higher odds of being prescribed an infusion DMA over an injectable DMA. In terms of healthcare utilization, older adults with outpatient visits had higher odds of being prescribed an infusion DMA over an injectable DMA, while older adults with inpatient visits had lower odds of being prescribed an infusion DMA over an injectable DMA.Nearly one in five older adults with MS are prescribed DMAs, with a majority receiving injectable DMAs. Several demographic and clinical factors were associated with DMA prescribing . This study fills the data gap regarding the utilization of DMAs in older adults with MS." @default.
• W3203399391 created "2021-10-11" @default.
• W3203399391 creator A5004112771 @default.
• W3203399391 creator A5004862775 @default.
• W3203399391 creator A5008079250 @default.
• W3203399391 creator A5060950455 @default.
• W3203399391 date "2022-01-01" @default.
• W3203399391 modified "2023-10-10" @default.
• W3203399391 title "Prescribing of disease modifying agents in older adults with multiple sclerosis" @default.
• W3203399391 cites W107839595 @default.
• W3203399391 cites W1720956115 @default.
• W3203399391 cites W1963878196 @default.
• W3203399391 cites W1967838438 @default.
• W3203399391 cites W1982303250 @default.
• W3203399391 cites W2010943878 @default.
• W3203399391 cites W2019582599 @default.
• W3203399391 cites W2044022462 @default.
• W3203399391 cites W2048000998 @default.
• W3203399391 cites W2048331974 @default.
• W3203399391 cites W2061326496 @default.
• W3203399391 cites W2061964547 @default.
• W3203399391 cites W2079478300 @default.
• W3203399391 cites W2089608136 @default.
• W3203399391 cites W2105206040 @default.
• W3203399391 cites W2107480122 @default.
• W3203399391 cites W2129967156 @default.
• W3203399391 cites W2131483615 @default.
• W3203399391 cites W2138414141 @default.
• W3203399391 cites W2146236437 @default.
• W3203399391 cites W2148563799 @default.
• W3203399391 cites W2148766438 @default.
• W3203399391 cites W2149658872 @default.
• W3203399391 cites W2151340435 @default.
• W3203399391 cites W2158202057 @default.
• W3203399391 cites W2158515030 @default.
• W3203399391 cites W2169804206 @default.
• W3203399391 cites W2270629863 @default.
• W3203399391 cites W2326826867 @default.
• W3203399391 cites W2328208048 @default.
• W3203399391 cites W2409482708 @default.
• W3203399391 cites W2410859287 @default.
• W3203399391 cites W2561881161 @default.
• W3203399391 cites W2586480138 @default.
• W3203399391 cites W2767362256 @default.
• W3203399391 cites W2768827063 @default.
• W3203399391 cites W2787483926 @default.
• W3203399391 cites W2791181325 @default.
• W3203399391 cites W2802733451 @default.
• W3203399391 cites W2897081589 @default.
• W3203399391 cites W2897332214 @default.
• W3203399391 cites W2905220597 @default.
• W3203399391 cites W2911658427 @default.
• W3203399391 cites W2935777701 @default.
• W3203399391 cites W3011959344 @default.
• W3203399391 cites W3030306741 @default.
• W3203399391 cites W3030389606 @default.
• W3203399391 cites W3031469252 @default.
• W3203399391 cites W3037344020 @default.
• W3203399391 cites W3095682907 @default.
• W3203399391 cites W3097683738 @default.
• W3203399391 cites W3149451384 @default.
• W3203399391 doi "https://doi.org/10.1016/j.msard.2021.103308" @default.
• W3203399391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35158421" @default.
• W3203399391 hasPublicationYear "2022" @default.
• W3203399391 type Work @default.
• W3203399391 sameAs 3203399391 @default.
• W3203399391 citedByCount "3" @default.
• W3203399391 countsByYear W32033993912022 @default.
• W3203399391 countsByYear W32033993912023 @default.
• W3203399391 crossrefType "journal-article" @default.
• W3203399391 hasAuthorship W3203399391A5004112771 @default.
• W3203399391 hasAuthorship W3203399391A5004862775 @default.
• W3203399391 hasAuthorship W3203399391A5008079250 @default.
• W3203399391 hasAuthorship W3203399391A5060950455 @default.
• W3203399391 hasConcept C117568660 @default.
• W3203399391 hasConcept C118552586 @default.
• W3203399391 hasConcept C119857082 @default.
• W3203399391 hasConcept C126322002 @default.
• W3203399391 hasConcept C143095724 @default.
• W3203399391 hasConcept C151956035 @default.
• W3203399391 hasConcept C156957248 @default.
• W3203399391 hasConcept C167135981 @default.
• W3203399391 hasConcept C195910791 @default.
• W3203399391 hasConcept C201903717 @default.
• W3203399391 hasConcept C2426938 @default.
• W3203399391 hasConcept C2780640218 @default.
• W3203399391 hasConcept C41008148 @default.
• W3203399391 hasConcept C71924100 @default.
• W3203399391 hasConcept C72563966 @default.
• W3203399391 hasConcept C98274493 @default.
• W3203399391 hasConceptScore W3203399391C117568660 @default.
• W3203399391 hasConceptScore W3203399391C118552586 @default.
• W3203399391 hasConceptScore W3203399391C119857082 @default.
• W3203399391 hasConceptScore W3203399391C126322002 @default.
• W3203399391 hasConceptScore W3203399391C143095724 @default.
• W3203399391 hasConceptScore W3203399391C151956035 @default.
• W3203399391 hasConceptScore W3203399391C156957248 @default.
• W3203399391 hasConceptScore W3203399391C167135981 @default.

• next